Business Context and Reporting Period
This Form 8-K is filed by Helix Acquisition Corp. II (HLXB), a Cayman Islands-based special purpose acquisition company (SPAC), on August 6, 2025. The filing discloses a material development regarding its proposed business combination with TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics, or "BBOT"). The report focuses on the outcome of shareholder redemptions following the initial public offering.
Key Financial Metrics
- Trust Account Retention: Following the redemption of Public Shares, Helix retained more than 60% of the funds in its Trust Account.
- Cash Proceeds: The retained amount is approximately $120 million.
- Revenue and Profit: The filing does not provide revenue, profit, or operating margin data for either Helix or BBOT.
- Debt and Liquidity: Specific debt obligations or liquidity ratios beyond the Trust Account balance are not detailed in this report.
Material Changes
The primary material change reported is the confirmation of the redemption activity. A significant portion of the Class A Ordinary Shares were redeemed, yet the company successfully retained over 60% of the initial trust capital. This outcome is critical as it impacts the minimum cash condition required to consummate the business combination with BBOT.
Guidance, Outlook, and Risks
Outlook: The filing indicates that the parties are proceeding toward the business combination, contingent on satisfying conditions such as the minimum cash requirement and Nasdaq listing standards.
Risks and Contingencies: The document includes extensive forward-looking statement disclaimers. Key risks identified include:
- Failure to successfully consummate the business combination.
- Inability to satisfy the minimum cash condition.
- Failure to meet Nasdaq's initial listing standards for the combined entity.
- Changes in market, financial, political, or legal conditions.
Unusual Items: The filing explicitly states that the information provided is furnished and not "filed" for purposes of Section 18 of the Exchange Act, limiting liability for the forward-looking statements contained within.
Investor Verification Checklist
- Verify the exact redemption percentage and final trust account balance in the definitive proxy statement/prospectus (File No. 333-288222).
- Confirm whether the $120 million retained satisfies the specific minimum cash condition required for the merger closing.
- Review the "Risk Factors" section of the July 10, 2025, proxy statement for detailed risks regarding the business combination.
- Monitor announcements regarding the final closing date and Nasdaq listing approval for the combined company.